PLX — Protalix BioTherapeutics, Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 1006281 ·
Last close
$2.44
Market Cap
$196.59M
52W High
$2.45
52W Low
$1.88
ADV30
647,662
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 33,750,000 | 29,623,000 | 21,146,000 | 18,317,000 | 102,336,000 | 41,001,000 | 35,107,000 |
| Dec 2025 | 9,122,000 | 4,503,000 | -4,658,000 | -5,504,000 | 82,346,000 | 14,680,000 | 34,116,000 |
| Sep 2025 | 17,851,000 | 9,527,000 | 2,131,000 | 2,355,000 | 82,264,000 | 13,647,000 | 29,356,000 |
| Jun 2025 | 15,658,000 | 9,788,000 | 1,172,000 | 164,000 | 78,486,000 | 17,895,000 | 28,583,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$15,090,000
Investing CF
$2,169,000
Financing CF
$4,400,000
CapEx
$-2,093,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.20
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-366,680,000
Inventory
$30,474,000
Receivables
$2,939,000
ST Investments
$10,082,000
EBIT TTM
$20,804,000
Pretax Income TTM
$19,265,000
Interest Exp TTM
$1,539,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$76,381,000
EBITDA
$21,314,000
Free Cash Flow
$6,783,125
Enterprise Value
$148,352,784
Total Cash
$51,083,000
Total Debt
$8,481,000
Shares Out
80,571,642
Trailing EPS
$0.19
Book Value
$0.83
ROE
27.3%
ROA
14.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 52,744,000 | -5,500,000 | -6,604,000 | 82,346,000 | 34,116,000 | — | -11,993,000 |
| Dec 2024 | 53,399,000 | 3,917,000 | 2,932,000 | 73,417,000 | 30,206,000 | — | 8,674,000 |
| Dec 2023 | 65,494,000 | 10,460,000 | 8,312,000 | 84,434,000 | 50,865,000 | — | -1,318,000 |
| Dec 2022 | 47,638,000 | -13,014,000 | -14,927,000 | 55,787,000 | 66,427,000 | — | -25,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.62
Max Pain — expiry 2026-08-21
max pain strike: $2.50 · spot: $2.44 · call oi: 1,239 · put oi: 1,261
Expected Move to 2026-08-21:
±$0.62
(25.61%) —
implied range
$1.82 –
$3.07
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRBU | Caribou Biosciences, Inc. | $190.92M | $1.92 | — |
| ABOS | Acumen Pharmaceuticals, Inc. | $189.96M | $2.63 | — |
| OTLK | Outlook Therapeutics, Inc. | $189.76M | $1.57 | — |
| TNYA | Tenaya Therapeutics, Inc. | $188.88M | $0.87 | — |
| HUMA | Humacyte, Inc. | $187.05M | $0.69 | — |
News headlines (Yahoo Finance, 1h cache)
3 Penny Stocks With Market Caps Larger Than $100M To Consider
2026-05-26 18:05 · Yahoo
PLX: Chiesi Milestone Received
2026-05-14 16:55 · Yahoo
Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary
2026-05-14 00:34 · Yahoo
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...
2026-05-13 23:02 · Yahoo
Transcript: Protalix BioTherapeutics Q1 2026 Earnings Conference Call
2026-05-13 12:19 · Yahoo
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
2026-05-13 10:50 · Yahoo
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
2026-05-06 10:50 · Yahoo
April 2026 Penny Stocks With Promising Potential
2026-04-10 18:05 · Yahoo
Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
2026-03-18 19:00 · Yahoo
PLX: 2025 Full Year Results
2026-03-18 17:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.